MX2020012480A - Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades. - Google Patents

Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.

Info

Publication number
MX2020012480A
MX2020012480A MX2020012480A MX2020012480A MX2020012480A MX 2020012480 A MX2020012480 A MX 2020012480A MX 2020012480 A MX2020012480 A MX 2020012480A MX 2020012480 A MX2020012480 A MX 2020012480A MX 2020012480 A MX2020012480 A MX 2020012480A
Authority
MX
Mexico
Prior art keywords
biomarker
disease
pbmc samples
protein levels
hsp70 protein
Prior art date
Application number
MX2020012480A
Other languages
English (en)
Inventor
Thomas Kirkegaard Jensen
Linda Ingemann
Original Assignee
Orphazyme As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphazyme As filed Critical Orphazyme As
Publication of MX2020012480A publication Critical patent/MX2020012480A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Aquí se describen los métodos basados en la identificación de los niveles reducidos de Hsp70 en las muestras de PBMC que sirven como un biomarcador para las enfermedades que se presentan con un nivel reducido de Hsp70, tales como las enfermedades de almacenamiento lisosomal, las enfermedades neurodegenerativas y las enfermedades musculares.
MX2020012480A 2018-05-28 2019-05-28 Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades. MX2020012480A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18174576 2018-05-28
PCT/EP2019/063854 WO2019229078A1 (en) 2018-05-28 2019-05-28 Hsp70 protein levels in pbmc samples as biomarker for disease

Publications (1)

Publication Number Publication Date
MX2020012480A true MX2020012480A (es) 2021-03-25

Family

ID=62455375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012480A MX2020012480A (es) 2018-05-28 2019-05-28 Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.

Country Status (12)

Country Link
US (1) US20210164997A1 (es)
EP (1) EP3803406A1 (es)
JP (1) JP2021525864A (es)
KR (1) KR20210015790A (es)
CN (1) CN112166326A (es)
AU (1) AU2019276048A1 (es)
BR (1) BR112020024182A2 (es)
CA (1) CA3101241A1 (es)
IL (1) IL278937A (es)
MX (1) MX2020012480A (es)
SG (1) SG11202011592SA (es)
WO (1) WO2019229078A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4124861A1 (en) 2021-07-31 2023-02-01 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Peripheral blood mononuclear cells (pbmc) phenotypes as biomarkers for patients with alzheimer's disease and/or mild cognitive impairment (mci)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HU226617B1 (en) 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PL2318032T3 (pl) * 2008-06-26 2012-08-31 Orphazyme Aps Zastosowanie hsp70 jako regulatora aktywności enzymatycznej
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
CA2847839A1 (en) * 2011-09-07 2013-03-14 Genway Biotech, Inc. Diagnostic assay to predict cardiovascular risk

Also Published As

Publication number Publication date
CA3101241A1 (en) 2019-12-05
BR112020024182A2 (pt) 2021-03-30
IL278937A (en) 2021-01-31
CN112166326A (zh) 2021-01-01
AU2019276048A1 (en) 2021-01-21
WO2019229078A1 (en) 2019-12-05
JP2021525864A (ja) 2021-09-27
KR20210015790A (ko) 2021-02-10
EP3803406A1 (en) 2021-04-14
US20210164997A1 (en) 2021-06-03
SG11202011592SA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
MY202410A (en) Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
EP3891755A4 (en) SYSTEM FOR IDENTIFICATION, EXTRACTION AND PREDICTION OF CLINICAL CONCEPTS AND ASSOCIATED PROCESSES
GB2539142A (en) Automatic interview question recommendation and analysis
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2019048927A3 (en) METHODS AND DEVICES FOR DETECTION OF BIOMARKERS ASSOCIATED WITH PRECLAMPSIA
EP2913689A3 (en) Proximity detection of candidate companion display device in same room as primary display using WI-FI or bluetooth signal strength
WO2015176066A3 (en) Lpa-associated protein and rna expression
AU2018262331A8 (en) Methods for trapping and barcoding discrete biological units in hydrogel
NZ751481A (en) Metabolite biomarkers for diseases associated with the contact activation system
SG10201901831XA (en) Method and system for determining relationship between users
EP3318878A3 (en) Prostate antigen standards and uses thereof
PH12019501369A1 (en) User credit assessment
WO2015193398A3 (en) Improved battery testing device
MX2019002929A (es) Biomarcadores de arn para angioedema hereditario.
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
EP3571315A4 (en) METHOD OF IDENTIFICATION AND USE OF SMALL RNA PREDICTORS
WO2016081885A3 (en) Panel-based genetic diagnostic testing for inherited eye diseases
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
EP2955649A3 (en) Digital health information system
MX2020012480A (es) Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP3888526A4 (en) EXAMINATION INSTRUMENT WITH AUTOMATIC SKIING DETECTION MECHANISM AND EXAMINATION PROCEDURE THEREOF
EP3734282A4 (en) DEVICE, REAGENT KIT AND METHOD FOR DETECTION OF MISFOLDED PROTEIN
WO2018187385A8 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING PANCREATIC CANCER